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Abstract 
Posterior capsule opacification (PCO) is the most common complication following 
cataract surgery and affects millions of patients. PCO is a consequence of surgical 
injury promoting a wound-healing response. Following surgery, residual lens epithelial 
cells grow on acellular regions of the lens capsule, including the central posterior 
capsule. These cells can undergo fibrotic changes, such that cell transdifferentiation 
to myofibroblasts, matrix deposition and matrix contraction can occur, which contribute 
to light scatter and the need for further corrective Nd:YAG laser capsulotomy in many 
patients. It is therefore of great importance to better understand how PCO develops 
and determine better approaches to manage the condition. To achieve this 
experimental systems are required and many are available to study PCO. While there 
may be a number of common features associated with PCO in different species, the 
mechanisms governing the condition can differ. Consequently, where possible, human 
systems should be employed. The human capsular bag model was established in a 
laboratory setting on donor eyes. A capsulorhexis is performed to create an opening 
in the anterior capsule followed by removal of the lens fibre mass. Residual fibre cells 
can be removed by irrigation/aspiration and if required, an intraocular lens can be 
implanted. The capsular bag is isolated from the eye and transferred to a dish for 
culture. The human capsular bag model has played an important role in understanding 
the biological processes driving PCO and enables evaluation of surgical approaches, 
IOLs and putative therapeutic agents to better manage PCO. 
 
  
Cataract surgery 
Cataract affects the vision and well-being of millions. At present the only means of 
treating cataract is through surgical intervention [1]. Modern cataract surgery involves 
making a small incision in the sclera or cornea to allow the surgeon to introduce 
surgical tools to the eye. The iris is dilated to improve the operating view. A central 
piece of the anterior capsule is typically removed by capsulorhexis. This allows the 
surgeon access to the lens fibre mass, which is often the cataractous region. This 
material is removed by phacoemulsification and on rare occasions by 
hydroexpression. This procedure generates a capsular bag, which comprises a ring of 
anterior lens capsule and the entire posterior capsule. Best efforts are made to remove 
residual fibre material from the capsular bag and an intraocular lens (IOL) implant is 
placed within it. In essence this procedure maintains separation of the aqueous and 
vitreous humours and through the introduction of the intraocular lens restores visual 
power.  
 
Posterior capsule opacification 
Initial surgical outcomes from cataract surgery are excellent, but with time lens cells 
that remain following the operation undergo a wound-healing response [2-4]. In effect, 
the trauma of surgery provokes cells to proliferate and migrate across the acellular 
capsular surfaces and in some case the IOL surface. Most importantly, cells ultimately 
grow on to the previously cell free central posterior capsule and undergo fibrotic events 
[2] that are associated with cell transdifferentiation to myofibroblasts, matrix deposition 
and matrix contraction that can lead to a secondary loss of vision termed posterior 
capsule opacification (PCO), which requires additional Nd:YAG laser capsulotomy if 
vision is sufficiently impaired [4]. PCO affects a large proportion of patients and is one 
of the most common fibrotic conditions in the world [2]. It is therefore of great 
importance to better understand this condition and thus powerful experimental 
systems are required for this purpose.  
 
 
The human capsular bag model  
Many experimental systems are available to study PCO, with each presenting their 
own strengths and weaknesses [1]. A major point of consideration is species variation 
[5]. While there may be a number of common features associated with PCO in different 
species the mechanisms governing the condition can differ. Consequently, where 
possible, human systems should be employed as these provide the best opportunity 
to fully understand the biological basis of human PCO and provide more relevant 
evaluation tools for pharmacological agents and implanted devices.  With this in mind, 
the human capsular bag model was developed [6-8] and has served as a valuable tool 
to understand the biological processes driving PCO [9-11] and to evaluate, surgical 
methods [12, 13], IOLs [14, 15] and putative therapeutic agents [16-20]. 
 
Establishing the model 
A key factor in the development of the human capsular bag model was the availability 
of human donor eyes. This valuable resource provided by the generosity of individuals 
and loved ones has enabled significant advances to be made that have and will 
continue to provide benefit to patients. In general, greater efforts are being directed to 
the use of human donor material for eye research, but maintaining a good supply of 
tissue is a priority [21]. The human lens in particular has biological features that further 
increase its value as an experimental system and relevance to clinical settings [5]. The 
first capsular bag models were established in the mid 1990s using human tissue [6, 
7], however the principle has been applied and adapted to other species [1].  
 
The capsular bag model is prepared following key steps performed in standard 
cataract surgery. The cornea is generally absent from donor eyes and the iris can be 
removed, which allows a clear view of the lens. A capsulorhexis is performed to create 
an opening in the anterior capsule followed by removal of the lens fibre mass. This 
latter procedure is generally carried out by hydrodissection rather than 
phacoemulsification. Residual fibre cells can be removed by irrigation/aspiration. If 
required, an intraocular lens can be implanted. The capsular bag is isolated from the 
eye and transferred to a dish for culture.  
 
Maintaining capsular bag shape  
Early models elected to isolate the capsular bag by cutting the zonules [6, 7]. Using 
this approach it is possible to work with pure populations of lens cells associated with 
the capsular bag, which aids experimental design and interpretation. This approach is 
particularly useful for studies aiming to understand the cell biological and physiological 
processes involved with human PCO. However, isolating the bag removes the forces 
provided by the zonules to maintain its shape. If simply grown in tissue culture the dish 
without support, the preparation would shrivel and form a coiled ball of contorted 
capsule and cells, which would provide limited information to researchers. To maintain 
the shape of the isolated capsular bag, two general approaches were adopted. The 
first was to use a ring [7], implanted with the capsular bag, to maintain shape, but this 
approach was not commonly adopted. Another approach was to secure the capsular 
bag to a culture dish using entomological pins (Figure 1) [6]. These pins penetrate the 
anterior and posterior capsules at the periphery of the bag and become embedded 
within the dish following a similar principle to a tent peg. Multiple pins (typically 8) are 
used to provide even support of the bag. This maintains the general shape of the bag, 
but also provides sufficient opportunity for cell-induced matrix modification to take 
place. Comments have been raised that the use of pins promote injury, but this should 
be placed in context with the surgical procedure itself, which is far more severe and is 
the fundamental stimulus for wound-healing events observed in the bag. Nevertheless 
penetrating the capsule does allow lens cells greater access to additional surfaces. 
The likelihood of cells advancing onto surfaces such as the peripheral outer anterior 
capsule and the culture dish are greatly influenced by the composition of the culture 
medium. Other approaches have aimed to establish a suspended capsular bag 
system, for example El-Osta et al [22] initially secured the periphery of the capsular 
bag to a lens holder using medical grade glue and introduced an IOL. This method 
was improved by Cleary et al. [8] through retention of the ciliary body and zonular 
fibres in association with the capsular bag. The ciliary body is pinned to a silicone ring 
leaving the capsular suspended in the lumen of the ring. Due to the presence of the 
ciliary body in this model, which introduces multiple cell types it is more complex to 
use this system to identify specific biological factors involved in specific events 
associated with PCO. It does however provide an excellent platform to assess general 
PCO progression and the influence of IOLs and pharmacological agents on PCO. 
 
Culture conditions 
As is common with in vitro cell and tissue culture, the standard culture conditions 
initially used was standard medium e.g. EMEM or DMEM supplemented with 
FCS/FBS; this was usually at 5-10% [6]. An antibiotic, usually gentamicin or 
penicillin/streptomycin, to ward off possible infections is also added. The purpose of 
supplementing the medium with FCS is to maintain cell survival and promote growth. 
It is however, important to note that in its natural setting the lens does not have direct 
access to a blood supply and is bathed in relatively poor environmental conditions. 
The fact that the lens can stay transparent for decades of life is testament to its 
endogenous survival skills, such that it is known that the lens produces many of the 
proteins within the aqueous humour that will in turn support its maintenance [23]. With 
this in mind, Wormstone et al [24] assessed the ability of cells within the human 
capsular bag to survive and grow in serum-free medium i.e. a simple culture medium 
(EMEM) with no added serum or protein supplements. Under these basal culture 
conditions, lens cells were found to not only survive, but grow across the posterior 
capsule. Strikingly, these cells were still actively synthesising proteins following more 
than a year in culture. This discovery greatly increased the value of the model. The 
use of high serum could be used to drive growth maximally if required. On the other 
hand, the ability to maintain cultures in serum-free medium provides a rare opportunity 
to assess the effects of a specific molecule or pathway through addition and inhibition 
studies, which allow assessment of cellular events within the capsular bag and 
analysis of the medium if desired.  
 
A number of factors have been identified using the capsular bag model to have 
putative roles in PCO formation through a combination of autocrine and paracrine 
regulation. A number of investigations using the capsular bag model have identified 
molecules that could play a role in survival and growth, which are key physiological 
events following surgery that form the foundation for PCO. Candidates identified 
through this approach include fibroblast growth factor [10], hepatocyte growth factor 
[25], thrombin[26], epidermal growth factor [27] and vascular endothelial growth factor 
[9].  
 
Fibrosis is a key aspect of PCO and features/markers for this have been identified in 
post-mortem capsular bag samples [2]. The most well documented molecule 
associated with fibrosis throughout the body is transforming growth factor β [28, 29]. 
It was therefore logical to study this molecule in the capsular bag model and see if 
TGFβ treatment in vitro could mimic changes observed in patients [11, 30, 31]. It was 
found that TGFβ was capable of promoting cell transdifferentiation to myofibroblasts, 
detected by alpha SMA expression, increased matrix production, enhanced matrix 
contraction and elevated levels of matrix metalloproteinases [11]. These changes 
mimicked findings from post-mortem capsular bag tissue [11]. It was discovered at a 
later date that a relatively short exposure of TGFβ was capable of inducing long-term 
effects i.e. maintain transdifferentiation and promote matrix contraction [31]. The 
knowledge that TGFβ can mimick clinical changes strongly implicate its involvement 
in human PCO. As a result introduction of TGFβ to the model can be used to promote 
fibrosis and permits investigation of the fundamental pathways and mechanisms 
driving fibrosis and PCO in a human system. 
 
 
Wherever possible it is good to use human products. The majority of the growth factors 
employed are human recombinant, but more recently efforts have been made to 
substitute FCS with human serum [15, 32]. This was initially maintained at a constant 
level throughout culture in order to drive growth in a similar manner to previous work 
employing FCS [14, 32]. However, changes to the ocular environment following 
cataract surgery are transient, peaking in the days week following surgery and return 
to a baseline state over time [33]. Eldred et al therefore set about making the 
maintenance conditions for capsular bag cultures better reflect the clinical scenario. 
To achieve this human serum was used to drive growth and TGFβ2 to promote fibrotic 
responses. Both human serum and TGFβ2 were added in a graded manner, such that 
cultures were exposed to maximum levels over the first 3 days of culture which was 
then reduced in a graded manner before continued maintenance of cultures for the 
remaining culture period in serum-free medium. As predicted growth and light scatter 
was accelerated (Figure 2) and fibrotic responses were enhanced (Figure 3) in graded 
culture. 
 
 
Assessing surgical techniques 
The human capsular bag model allows surgical methods to be compared in relation to 
cell behaviour and PCO progression. For example, Quinlan et al [13] compared the 
impact of different methods to remove the fibre mass, namely hydroexpression and 
phacoemulsification. Match-paired capsular bags were maintained in serum-free or 
serum supplemented culture conditions following surgery. No difference in cell survival 
and growth was observed. Any benefits in patients from phacoemulsification relative 
to hydroexpression are likely to result from the smaller incision size and reduced 
inflammation due to this [34]. Therefore, in the laboratory setting either method is 
applicable and will ultimately perform the same role. The capsular bag model has also 
been used to assess if femtosecond laser capsulotomy could alter PCO formation 
relative to conventional manual capsuorhexis; in this study they concluded that no 
significant difference was observed [12].   
 
Evaluation and development of IOLS 
The most commonly used experimental system to evaluate intraocular lenses is the in 
vivo rabbit model [35, 36]. This is largely due to the size of the rabbit lens being similar 
to a human lens and the argument that it offers an accelerated form of PCO.  Human 
capsular bag models provide an alternative model for IOL research and development 
[6, 8, 14, 15, 18, 32, 37]. For example, the capsular bag model contributed greatly in 
the development of the Bag-in-the-lens IOL developed by Prof. Tassignon [37], which 
is now a commercially available IOL used successfully in clinical practice. The model 
has been developed and further improved over time in order to better enable IOL 
development. The original capsular bag model was first used to investigate the effect 
of IOLs [6]. This model secured the capsular bag (anterior surface up) to a dish using 
entomological pins at the equator, which resulted in a major point of contact with the 
capsule at the centre of the optic and weak interaction at the optic edge. To improve 
the interaction between the capsule and optic, to better reflect the in vivo scenario, 
Dawes et al [32] inverted the bag containing an IOL i.e. secured the bag containing 
the IOL anterior capsule down. This approach provided greater interaction between 
the optic edge and allowed the barrier effect seen with square edge IOLs to be studied. 
In addition, Dawes et al [32] fully humanised this system using human serum and 
human recombinant TGFβ2 to drive growth and fibrosis. The introduction of 
suspended capsular bag models, however has enhanced the utility of the bag model 
to study the effects of IOLs on PCO. As described earlier suspended capsular bag 
models maintain capsular bag integrity and allow the IOL to sit within it in a similar 
manner to in vivo [8, 15] (Figure 4). The suspended model has been used to determine 
that IOL stability can be affected by an absence of lens cells [38]. Therefore, if efforts 
to ablate the residual cell population, by surgical or pharmacological means, are 
adopted in the future, modification of IOL design to improve stability in a cell-free bag 
is required. The suspended capsular bag model has also been used to test an open-
bag IOL (Anew Zephyr) against the Alcon Acrysof [14]. The Alcon Acrysof is a 
traditional closed bag device that permits contact between the anterior and posterior 
capsules. The consequence of this is to “shrink wrap” the IOL, which is believed to 
provide a greater barrier at the edge of the IOL optic. This theoretically is believed to 
impede cell movement and ultimately PCO. It is known clinically that standard square-
edge closed bag IOLs such as Alcon Acrysof slow, but do not prevent PCO. The Anew 
Zephyr IOL in contrast partitions the anterior and posterior capsules. The Anew Zephyr 
IOL outperformed the Alcon Acrysof in each match-paired experiment performed and 
suggest this fundamental design is worthy of development in the future [14]. These 
previous studies assessing IOLs in the bag had typically used constant serum levels 
or employed serum-free conditions. As this doesn’t reflect the transient nature of 
proteins in the aqueous humour following cataract surgery, the graded culture model 
was employed to compare two common square-edge hydrophobic acrylic IOLs (Hoya 
Vivinex and Alcon Acrysof) under environmental conditions more reflective of the 
clinical scenario [15]. The graded culture regime provides a direct stimuli to residual 
lens cells following surgery. Using this approach, key observations of cell growth can 
be obtained on both the posterior capsule and IOL surface. In addition light scatter, 
myofibroblast expression and matrix deposition can be determined at end-point[15]. It 
should also be noted that many of the factors present in serum and supplemented 
TGFβ2 can bind to the lens capsule [31, 39]. This essentially means that the capsule 
provides a reservoir of growth factors that can continue to regulate cells long after the 
external stimulus has been removed. Enrichment of the IOL by serum and added 
proteins is likely to be less long-lived than on the capsule. As culture progresses, 
growth on the IOL can recede to some degree, which links well with clinical 
observations [40]. At present the graded culture in conjunction with a suspended 
capsular bag model appears to provide the best in vitro system to evaluate and 
develop IOLs [15]. 
 
 
Putative therapeutic agents and drug delivery 
While improving IOL design to better manage PCO is logical, it is also likely that 
additional treatments using therapeutic agents or additional surgical approaches will 
be required to significantly reduce PCO formation and incidence. A recent paper has 
also indicated that this is a view held by a number of clinicians [41]. The capsular bag 
model has served as a valuable tool to test a number of therapeutic approaches. 
Therapeutic benefit could be derived from a number of strategies including complete 
ablation of cells within the bag [17, 18, 42, 43], prevention of matrix contraction/light 
scatter  [19, 20, 31] or inhibit growth/migration [9, 20, 44, 45]. When the intention is to 
deliver a pharmacological agent it is important to consider how the agent can be 
delivered in a safe and effective manner. Again the human capsular bag model has 
been used to assess drug delivery strategies. For example, the IOL itself can serve as 
a drug delivery device through surface coating and modification [16, 18, 45]. In 
addition, sealed drug delivery systems have also been used, which allow controlled 
drug exposure to lens cells within the capsular bag, but protects other ocular tissues 
[17, 46]. In one study, double distilled water was delivered to the in vitro human 
capsular bag using the perfect capsule system with the intention of killing all cells at 
the time of surgery [17]. Interestingly, this approach was also performed in actual 
cataract surgery[46]. In both cases the epithelium had a frosted appearance following 
surgery. This treatment did not successfully kill the entire lens epithelial cell population, 
but did provide some slowing in the progression of PCO. This relative comparison of 
outcomes between the clinic and the human capsular bag model further highlights the 
value and predictive power this in vitro human model can provide.   
 
Summary 
The Human capsular bag model provides an in vitro experimental system that reflects 
the clinical scenario following cataract surgery. The unique properties of the lens allow 
the culture environment to be controlled, which enables greater resolution of the 
factors regulating PCO progression.  The human capsular bag model also permits 
evaluation of putative therapeutic agents with a stronger predictive power than is 
possible with animal models. In addition, the human capsular bag model can be used 
to assess and develop current and prototype IOL designs. The capsular bag model 
has therefore made a significant impact on PCO research and will continue to play a 
key role in developing strategies to better manage this common condition. 
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Legends 
Figure 1. Low-power, modified dark-field superior view of a human capsular bag 
preparation, secured to a culture dish using entomological pins and immersed in 
culture medium. 
. 
Figure 2. Assessment of growth characteristics and matrix modification in capsular 
bags maintained under graded culture (Days 1-3, 5% Human serum and 10ng/ml 
TGFβ2; Days 4-7, 2% Human serum and 1ng/ml TGFβ2; Days 8-14, 1% Human 
serum and 0.1ng/ml TGFβ2; Days 15-28 serum-free) or serum-free (SF) culture 
conditions. Progressive movement of cells (leading edge indicated by white arrows) 
was observed, initially on the peripheral posterior capsule (Day 7), then beyond the 
rhexis margin (black arrows) onto the central posterior capsule (days 14, 21 and 28). 
Note that wrinkling of the posterior capsule is associated with movement in graded 
cultures, whereas serum-free cultures exhibit matrix wrinkling once movement has 
been arrested. [15] 
 
Figure 3.  Representative epifluorescence micrographs showing the distribution of the 
myofibroblast marker, α-smooth muscle actin and the matrix component, fibronectin 
associated with cells growing on the central posterior capsule of human lens capsular 
bag preparations maintained in serum-free (SF) or graded culture conditions. Images 
were captured at end-point (Day 28). [15] 
 
Figure 4. Representative modified dark-field images of match-paired capsular bags 
implanted with a Hoya Vivinex or an Alcon Acrysof IOL captured on the day of 
simulated surgery. In both cases the capsulorhexis (arrowed) is fully seated on the 
IOL optic. [15] 
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